Table 1. Baseline characteristics and regimens used for induction treatment in 381 patients with PM/DM-associated ILD.
| Variables | Value | Available data per outcome |
|---|---|---|
| Demographics | ||
| Age at onset, years | 56 ± 12 | 381 (100%) |
| Female, no (%) | 253 (66) | 381 (100%) |
| Disease duration at diagnosis, month | 2 [1–5] | 381 (100%) |
| Diagnosis | ||
| PM, no (%) | 48 (13) | 381 (100%) |
| Classic DM, no (%) | 119 (31) | 381 (100%) |
| CADM, no (%) | 214 (53) | 381 (100%) |
| Pulmonary function testing | ||
| %Vital capacity, predicted | 77 (63–92) | 309 (81%) |
| %DLco, predicted | 61 (48–78) | 262 (69%) |
| Laboratory parameters | ||
| CRP, mg/dL | 0.7 (0.2–1.8) | 378 (99%) |
| Ferritin, ng/mL | 348 (134–721) | 285 (75%) |
| KL-6, U/mL | 830 (547–1296) | 381 (100%) |
| SP-D, ng/mL | 91 (45–175) | 381 (100%) |
| MSAs | ||
| Anti-ARS antibody, no (%) | 131 (34)* | 381 (100%) |
| Anti-MDA5 antibody, no (%) | 170 (45)* | 381 (100%) |
| Double-negative, no (%) | 81 (21) | 381 (100%) |
| Regimens used for induction treatment | ||
| CS alone, no (%) | 56 (15%) | 381 (100%) |
| CS + IVCY, no (%) | 13 (3%) | 381 (100%) |
| CS + CNI, no (%) | 146 (38%) | 381 (100%) |
| CS + IVCY + CNI, no (%) | 166 (44%) | 381 (100%) |
Continuous variables are shown as median [interquartile range].
*One patient was positive for both anti-ARS and MDA5 antibodies.
PM: polymyositis, DM: dermatomyositis, CADM: clinically amyopathic dermatomyositis, DLco: diffusing capacity for carbon monoxide, CRP: C-reactive protein, MSA: myositis-specific autoantibody, ARS: aminoacyl tRNA synthetase, MDA5: melanoma differentiation-associated gene 5, CS: corticosteroid, IVCY: intravenous cyclophosphamide, CNI: calcineurin inhibitor